Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period - Phase II exploratory study.

Trial Profile

Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period - Phase II exploratory study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2013

At a glance

  • Drugs Aladorian (Primary)
  • Indications Ventricular arrhythmias
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 23 Jun 2012 Additional locations (Brazil, Canada, Czech Republic, Hungary, Italy, Slovakia and Taiwan ) added as reported by European Clinical Trials Database.
    • 21 Apr 2012 Planned end date 1 Jun 2013 added as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Additional trial locations (Netherlands and United Kingdom) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top